Vim & Vigor - Spring 2011 - Community Healthcare - (Page 38)

HEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS ROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST ENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASISfor some good news: U.S. cancer death Now PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASISAmerican rates are declining. According to the PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTCancer Society’s cancer statistics report, cancer PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT death rates fell 21 percent PROSTATE-SPECIFIC ANTIGEN ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTamong men and 12 percent among women from MAMMOGRAPHY PAP TEST EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN 1991 to 2006. “Cure rates seem to be improving ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY because CARCINOGEN more people are undergoing regular screenings, AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY and treatments are becoming more targeted,” UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS says Gary Shelton, N.P., a spokesman for the ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTOncology Nursing Society. PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTterminology is the ﬁrst Understanding cancer PROSTATE-SPECIFIC ANTIGEN hen your doctor says, “You EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST step in educating yourself about cancer so you have cancer,” your world ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN can face it head-on. Read on to learn more about common cancer terms you may encounter. stops. It’s confusing, sad AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS and downright scary. But ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTPREVENTION AND DETECTIONMALIGNANT PROSTATE-SPECIFIC ANTIGEN TEST BENIGN it’s an unfortunate reality that many of us CARCINOGEN: TEST PROSTATE-SPECIFIC ANTIGEN ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP“Anything that has been shown to cause cancer is a carcinogen,” says will have to PROGNOSIS RECURRENCE CHEMOTHERAPY EST BENIGN MALIGNANT METASTASIS face ourselves or with a fam- LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST Shelton. Cigarette smoking, too much sun and ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASISmen and RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN ily member. In fact, one in two PROGNOSIS exposure to certain chemicals, such as asbestos, AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY are carcinogens. women in the U.S. PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST commonMALIGNANT METASTASIS PROGNOSIS will be diagnosed with UMPECTOMY CARCINOGEN MAMMOGRAPHY TIP:BENIGN made the lifesaving decision to stop You’ve cancer in their lifetimes, according to the ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTsmoking, but if youANTIGEN TEST BENIGN MALIGNANT PROSTATE-SPECIFIC notice people around you ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN lighting up, talk to them about your commitment National Cancer Institute. to health. Ask that they refrain from smoking EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST around you. ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY 38 Vim & Vigor · SP R I N G 2 011 UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT FIGHTING Understanding cancer terms can help you come out swinging BY JULIE WLODYCHAK W

Table of Contents for the Digital Edition of Vim & Vigor - Spring 2011 - Community Healthcare

Vim & Vigor - Spring 2011 - Community Healthcare
Contents
Community Message
Community Briefs
Solutions for Relief
Helping the Medicine Go Down
Beating Breast Cancer
A Workout for Every Mood
Don’t Fail Your Heart
If Your Bones Could Talk
Healthy Travels
Over 40 and Fabulous
Do-It-Yourself Health?
Fighting Words
Balancing Act
Giving & Getting
The Heart of Rehab
Spotlight on St. Mary Medical Center
Spotlight on Community Hospital
Spotlight on St. Catherine Hospital
Prescription for Safety

Vim & Vigor - Spring 2011 - Community Healthcare